Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llae145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Catherine Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic urticaria (CU) is characterized by weals (hives) angio-oedema (or both) that last for ≥ 6 weeks, with chronic spontaneous urticaria (CSU) being the most common subtype. Patients with omalizumab-refractory CSU represent an unmet clinical need. In this study, we aimed to assess the prevalence and predictors of omalizumab failure in a large cohort of patients with CU and assess the effectiveness of dupilumab for omalizumab-refractory CU. Of 338 patients with CU, 33 received omalizumab; 69.7% (n = 23) were responders and 30.3% (n = 10) were nonresponders. Bivariate regression demonstrated that female sex [adjusted odds ratio (aOR) 1.53, 95% confidence interval (CI) 1.14–2.06], higher baseline weekly urticaria activity score (aOR 1.05, 95% CI 1.01–1.09) and older age (controlling for sex) (aOR 1.00, 95% CI 1.00–1.01) were associated with omalizumab failure. Of 10 patients with omalizumab-refractory CU, 3 were well controlled with ciclosporin (all children), whereas the 7 adults failed a mean [standard deviation (SD)] of 5.6 (2.6) treatments, including ciclosporin. All seven achieved a complete response with dupilumab, with time to response varying between 1 and 6 months. While our results suggest a favourable efficacy of dupilumab in patients with omalizumab-refractory CU, future confirmatory studies are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, McGill University, Montreal, QC, Canada.
- Division of Dermatology, McGill University, Montreal, QC, Canada.
- Centre for Outcomes Research and Evaluation, McGill University Health Centre Research Institute, Montreal, QC, Canada.
- Division of Allergy and Clinical Immunology, McGill University, Montreal, QC, Canada.
- Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University, Montreal, QC, Canada.
ORCID-Profile: Connor Prosty
Zitieren
APA
Zhu, C., BinJadeed, H., Gabrielli, S., Prosty, C., Rahme, E., Shand, G., Fein, M., Ben-Shoshan, M., & Netchiporouk, E. (2024). Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae145
Vancouver
Zhu C, BinJadeed H, Gabrielli S, Prosty C, Rahme E, Shand G, et al. Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae145
BibTeX
@article{Zhu2024,
author = {Zhu, Catherine and BinJadeed, Hessah and Gabrielli, Sofianne and Prosty, Connor and Rahme, Elham and Shand, Greg and Fein, Michael and Ben-Shoshan, Moshe and Netchiporouk, Elena},
title = {Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llae145}
}
EUVIMED